Gan & Lee’s weekly insulin meets goals in phase 3 trials

Gan & Lee's once-weekly insulin GZR4 met primary endpoints in two Phase 3 trials: SUPER-1 (n=588) showed HbA1c change -1.45% vs -1.22% (between-group difference -0.23%) and SUPER-2 (n=631) showed -1.00% vs -0.58% (difference -0.42%) at 26 weeks, with no severe hypoglycemia reported in either trial. The SUPER program totals ~2,120 patients; detailed results will be presented and submitted for publication. Investors have reacted positively (shares +8.4% over the past week); company fundamentals cited include a 75% gross margin and 31% revenue growth LTM, supporting upside if regulatory path proceeds smoothly.

Analysis

A domestic once‑weekly basal insulin that clears late‑stage trials pulls more than just share from daily basal incumbents — it alters the procurement economics of Chinese hospital formularies and the consumables chain. Fewer injections per patient reduces recurring revenue for pen/needle manufacturers and may compress unit demand for vials/pens by a mid‑single to low‑double digit percentage over 3‑5 years in the target markets, while raising the importance of injector design, patient support and adherence services as differentiators.

Commercial success will hinge on three non‑clinical vectors: NMPA regulatory acceptance and label breadth (timing: 12–18 months), placement in provincial hospital bidding and national reimbursement lists that dictate price expectations, and real‑world safety/CGM outcomes that influence specialist adoption. Each vector has asymmetric friction — fast regulatory acceptance without NRDL inclusion yields limited volume; NRDL access without convincing post‑market safety/weight data caps price.

Near term, market moves are primarily binary/flow driven and likely overprice implied commercialization certainty. The right approach is staging exposure: capture upside from a domestic brand gaining a structural channel advantage while protecting against regulatory, reimbursement and competitive responses from well‑capitalized global players who can undercut pricing or launch rival weekly products within 12–36 months. Watch hospital procurement notices, provincial volume allocations and upcoming conference presentations as 1–6 month catalysts that will materially reprice risk.

Key Decisions for Investors

• Long SSE:603087 (small starter position, 3–5% portfolio cash exposure): accumulate on intraday weakness or a 10–20% pullback. Time horizon 12–18 months targeting 30–60% upside conditional on NMPA acceptance and national reimbursement; hard stop at 20% to guard against regulatory or manufacturing setbacks.
• Paired trade — Long SSE:603087 / Short NVO (0.2x notional): size the short to cap beta (e.g., 1:0.2). Rationale: isolate China share gains while hedging global risk. Timeframe 12 months; expected asymmetric payoff if domestic adoption outpaces incumbent pricing responses. Risk: Novo’s durable global cash flow cushions downside if competition intensifies elsewhere.
• Tactical underweight / small short BDX (Becton Dickinson) or Chinese pen/needle OEMs (select names): horizon 12–36 months targeting 10–20% downside as injection frequency normalizes lower. Keep position small (1–2% portfolio) and monitor device adoption shifts and any pivot to combination pen systems that could blunt consumables decline.